NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 58.19

+0.3%

11:52 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (309)	5/21/2010 8:22:40 AM
From: david nordic	Read Replies (1) of 507

NKTR 102 (Pegylate Irinotecan) RECIST responses (confirmed and unconfirmed) were 27% and 22% for the q14d and q21d schedules. One dose level 145mg/m2. Irinotecan with a half life of 30-40 hours vs NKTR 102 with a half life of 50+ days. The patient can back off the dose scheduling from 2 weeks to three weeks and still response to NKTR 102. Ovarian Cancer NKTR 102 is both less toxic and more effective. Other treatment range from RECIST (6.5-16) with Avastin at 16. Patients are still on NKTR 102 after being treated with 6 prior treatments. NKTR 102 is also in Breast Cancer and Colon Cancer studies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next